,
2 min read
South Korea new drug approval process is a critical Regulatory pathway for pharmaceutical and biotechnology companies seeking market entry into one of Asia’s most advanced healthcare systems. With a rapidly evolving Regulatory landscape and increased global harmonization, understanding this framework is essential for successful product registration.
The New Drug Application (NDA) and Biologics License Application (BLA) processes are the primary Regulatory routes for introducing new chemical drugs and biologics into the South Korean market.
South Korea New Drug Approval Process: Regulatory Authority and Oversight
The Ministry of Food and Drug Safety (MFDS) is South Korea's national authority
responsible for evaluating pharmaceuticals and biologics before granting market authorization.
The MFDS review process assesses multiple aspects of a product, including:
- Clinical safety and efficacy
- Chemistry, Manufacturing & Controls (CMC)
- Good Manufacturing Practice (GMP) compliance
- Product labeling and risk management
The MFDS pharmaceutical product approval Korea framework has undergone significant modernization recently to enhance predictability and transparency.
Main Steps in the Korea NDA and BLA Process:
- Pre-Submission Consultation
Companies are encouraged to engage in early consultations with MFDS prior to submitting an application. These meetings help clarify regulatory expectations and align submission strategies. Typical discussion topics include:
- Dossier requirements and format
- Clinical development strategy
- Data expectations for approval
Early engagement with regulators can significantly improve efficiency and reduce review delays.
- Application Submission
Applicants must submit a comprehensive dossier including:
- Clinical trial data demonstrating safety and efficacy
- Nonclinical study data
- Manufacturing and process information
- Quality control Documentation
- Risk management plans
Since January 1, 2025, the review fee for new drug approval applications submitted to MFDS is approximately KRW 410 million.
These submission requirements form the foundation of the Korea NDA and BLA process, ensuring scientific rigor and Regulatory compliance.
- Manufacturing and Quality Assessment
Manufacturing compliance plays a central role in the South Korea pharmaceutical Regulatory guidelines.
MFDS conducts:
- Good Manufacturing Practice (GMP) inspection of manufacturing facilities
- Product-specific quality evaluation
- Onsite investigation within 90 days of application receipt
The mandated 90-day GMP assessment period increases timeline predictability for applicants navigating the South Korea new drug approval process.
- Formal Review Process
After acceptance, MFDS assigns a reviewer to evaluate:
- Clinical efficacy
- Safety profile
- Manufacturing controls
- Product labeling and indication
As part of the new review framework, formal interactions between the applicant and MFDS reviewers have been expanded to up to 10 consultation meetings (previously up to 3), with outcomes documented to improve transparency and review efficiency. This increased interaction significantly enhances clarity during the MFDS drug approval Korea review phase.
Timeline for this stage is typically within 90 days for the GMP inspection; full review timing varies with product type and complexity.
- Decision and Approval
Upon satisfactory evaluation:
- NDAs receive market authorization
- BLAs receive biologics manufacturing licenses
Approval allows companies to commercially distribute the product in the South Korean market, subject to applicable post-approval regulatory requirements.
- Post-Approval Obligations
Following approval, companies must maintain compliance with:
- Pharmacovigilance requirements
- Periodic safety reporting
- Continued GMP adherence
These obligations ensure long-term product safety and Regulatory compliance under the South Korea pharmaceutical Regulatory guidelines.
Summary
Stage | Key Activities | Key Timelines / Notes |
| Pre-Submission Consultation | Discussion on dossier requirements and Regulatory strategy | Recommended prior to submission to reduce review gaps |
| Application Submission | Submission of clinical/ nonclinical data, manufacturing information, and quality documentation | Licensing fee: KRW 410 million (effective Jan 1, 2025) |
| Manufacturing & Quality Assessment | GMP inspection, product-specific quality evaluation, onsite inspection | Onsite inspection within 90 days of application receipt |
| Formal Review Process | Evaluation of safety, efficacy, CMC, and labeling | Up to 10 official communications allowed; GMP review within 90 days |
| Decision & Approval | Granting of market authorization (NDA) or biologics manufacturing license (BLA) | Enables commercial distribution in South Korea |
| Post-Approval Obligations | Pharmacovigilance, periodic safety reporting, continued GMP compliance | Ongoing lifecycle management required |
Conclusion
The South Korea new drug approval process provides a structured and increasingly predictable Regulatory pathway for pharmaceutical and biologic products.
Partnering with experienced Regulatory experts such as Freyr can further streamline submissions, ensure compliance with MFDS expectations, and accelerate successful market entry into South Korea’s highly competitive pharmaceutical landscape.
